- Fragile X-associated Disorders
- Treatment & Intervention
- Support the NFXF
The Fragile X Clinical & Research Consortium (FXCRC) is a group of clinics and research facilities across the United States that are dedicated to assisting families and individuals who are affected by fragile X syndrome (FXS) or one of the other Fragile X-associated Disorders. Most clinics are part of university and/or hospital settings. There, experts in the field of FXS can offer medical, therapeutic, and educational evaluations, treatment recommendations, and referrals to other important resources. The information gathered from patients and families can help expand knowledge about FXS to guide future treatment.
One of the best ways for families to help their doctors gather this information is to become part of the FORWARD Registry and Database.
Clinical trials (studies involving humans with the actual condition) of new medications for the treatment of Fragile X-associated Disorders (FXD) are currently underway at many sites throughout the U.S. and the world. These trials involve individuals with a FXD, including fragile X syndrome. Typically, these trials are sponsored by a pharmaceutical company seeking to determine the effectiveness of a new drug. Sometimes the studies involve older drugs previously used for treatment of conditions other than Fragile X. Studies typically go through three phases prior to being considered for approval by the government. Phase III studies begin only after effectiveness has been shown to occur in animals and after safety has been proven in individuals without a Fragile X disorder.
To ensure that the effects of the drugs are not influenced by the researchers hopes or expectations, most studies are “double-blind, placebo controlled.” That is, the researcher/clinician, prescribing the drug does not know who is receiving the actual drug and who is receiving a placebo (sugar pill). The parents or the actual participant also does not know. This process is considered the “gold-standard” of medical studies and helps make sure that only truly effective medicines end up as treatments.
Since these are studies only, following the conclusion of the study, in most cases the participants must stop taking the drug. However, in some placebo-controlled studies, all participants are allowed to go on the medication (not placebo) through a so-called “extension.” In this case usually the company is collecting data about long-term safety of the drug and the extension may go on for variable amounts of time, sometimes even until the drug is approved by the government. Should the studies prove that the drug is safe and effective, and once the drug is approved by the U.S. Food and Drug Administration (FDA), the individual may be prescribed the medication by his or her physician.
Not all studies involve drugs. Studies can involve behavior, language development and other important areas of intervention and development. These studies are as important as drug studies and will help doctors, therapists, educators and counselors improve treatments as well as take better advantage of new opportunities that may result from new drugs.
The NFXF also periodically assists with research recruitment through a variety of means including mailings, email blasts and Facebook postings. This is a fee-based service designed to promote the advancement of Fragile X research including on behalf of university-based researchers, pharmaceutical companies, and others who meet our general guidelines, while compensating the NFXF for the associated staff time and materials expense. If you prefer to not receive these notifications please click here.
If you are a family member and have any questions about a specific study, please use the contact information listed on the clinic’s announcement. If you are a professional and have any questions about how the NFXF can assist you with recruitment, please call (925) 938-9300.
If you have a son with fragile X syndrome between 36 and 66 months of age, you and your child are invited to participate in a research study being conducted by Dr. Angela Thurman from the Laboratory on Language Development in Neurodevelopmental Disorders at the MIND Institute University of California, Davis. Study Goals The goal of this study is to learn more about the factors influencing language learning in boys with fragile X syndrome. In the future, it is possible that this information will help us... » FULL ARTICLE
Dear Families, You are invited to take part in a fragile X syndrome (FXS) study for racial and ethnic minority children and families by taking an online survey. The researcher, Georgianna Baker-Gay, is a Public Health doctoral student at Capella University. In partial fulfillment of the requirements for the Degree Doctor of Public Health, the researcher has chosen to examine the needs of FXS racial and ethnic minority children and families. The purpose of the study is to create a racial and ethnic minority Fragile X awareness and education program intended to improve identification and management of FXS... » FULL ARTICLE
Purpose of Study To better understand the emotional experiences and experiences with support systems of mothers who are carriers of fragile X syndrome and have had a child diagnosed in the first three years of life. Determine if there is a change in emotional intensity or a change in the types of support available and utilized by mothers before versus after a child is diagnosed with fragile X syndrome. Determine if there is a correlation between emotional intensity and types of support utilized before and after a child... » FULL ARTICLE
Participate in Fragile X research from anywhere! This research study is looking at the relationship between sensory processing skills (response to sensory experiences) and the development of daily life skills (adaptive skills). The goal of this research study is to find out more information about what daily living skills children with Fragile X are developing as they grow up, and how their ability to process sensory experiences contributes to their performance and behavior. Who can participate? Parents who have a child with full mutation Fragile X. Child... » FULL ARTICLE
The Carolina Institute for Developmental Disabilities (CIDD) at the University of North Carolina at Chapel Hill and the Center for Interdisciplinary Brain Sciences Research (CIBSR) at Stanford University would like to inform you of an exciting new research project involving families who have a child diagnosed with fragile X syndrome. This innovative, five-year, NIMH funded research project was awarded $5 million in funding in the fall of 2012 and the study is now underway. The... » FULL ARTICLE
Researchers at the University of Michigan are looking for fathers of children with fragile X syndrome to participate in a survey about their parenting experiences. Previous research has focused on how moms cope. This time, we want to hear from dads! To participate you must be 18 years or older, male, and a parent (biological or adoptive) of at least one child with fragile X syndrome. If you choose to participate in this study, you will be helping us better understand dads’ experiences with FXS and... » FULL ARTICLE
We are interested in learning if a behavioral treatment called Parent- Implemented Language Intervention will support spoken language development in boys with fragile X syndrome (FXS). This study might be a good fit for you if: You are the mother of a 10-17 year old son with fragile X syndrome. Your native language is English. Your son uses phrases of 2-3 words or longer. If you decide to take part in the study: You and your son would need to come to the MIND Institute for 2 visits,... » FULL ARTICLE
This research seeks to understand how protein formation in the brain is affected in fragile X syndrome (FXS). Researchers will measure the rate at which the brain makes proteins (protein synthesis) and will identify specific parts of the brain affected in FXS. In the future, measurement of protein synthesis in FXS may help us to develop and test new therapies. The study enrolls eligible young men with FXS, ages 18-24, from around the world, and includes: One visit, lasting several days, to the NIH Clinical Center, in Bethesda, Maryland. Assessment by physicians Blood draw, Two brain scans (PET & MRI), possible sedation Travel, food, and... » FULL ARTICLE
Alcobra is pleased to let you know about a new clinical trial that is currently underway and recruiting patients with fragile X syndrome. The study is seeking male and female participants between the ages of 15 and 55 who have been diagnosed with fragile X syndrome. This clinical trial is studying the effects of a medicine on the cognitive and inattentive symptoms in people with fragile X syndrome. The trial is taking place in 12 U.S. cities. You will not be charged money to participate in this trial. In fact, expenses for travel... » FULL ARTICLE
Does someone you love have fragile X syndrome (FXS)? If so, please know that we are currently enrolling individuals with FXS between 15 and 55 years of age to participate in a medical research study. In this research study, we will evaluate the effects of the investigational drug Metadoxine Extended Release (MDX) on the symptoms of ADHD in individuals with Fragile X. There is no cost to participate in our research study, and compensation for time and travel may be available. To learn more about our research study, please contact: Libby Bliss, Research Manager 206-884-1488 email@example.com Seattle... » FULL ARTICLE
Neuren Pharmaceuticals is pleased to inform you of an opportunity to participate in a clinical trial for adolescents and adults with fragile X syndrome. This clinical trial is testing an investigational medication, NNZ-2566, as a targeted treatment for fragile X syndrome (FXS). The purpose of this study is to assess the safety and efficacy of two dose levels of NNZ-2566 when compared to placebo in adolescent and adult males (ages 14-40) who have been diagnosed with FXS.NNZ-2566 has an entirely novel mechanism of action compared with other drugs that have been... » FULL ARTICLE
Alcobra Ltd will be conducting a clinical trial of Metadoxine Extended Release (MDX) in adults and adolescents, 15 to 55 years old, with fragile X syndrome. The planned Phase IIb MDX clinical trial will be a multi-center, randomized, placebo-controlled study, conducted primarily in the US. The study is supported by positive data collected from multiple earlier animal studies using metadoxine. Results from these studies demonstrated significant improvement in behavioral and cognitive outcomes in mice based on testing and performance of memory, learning, and social interaction. » FULL ARTICLE
We are recruiting a small group of mothers and their children with fragile X syndrome, between the ages of 10- and 17-years, to participate in a pilot study of a parent-implemented language intervention. The goal of this project is to teach each mother strategies which can be used to support spoken language development in their child with fragile X syndrome. » FULL ARTICLE
If you have a son with fragile X syndrome or a son with autism between 15 and 22 years of age, you and your son are invited to participate in a research study being conducted by Dr. Leonard Abbeduto at the MIND Institute University of California, Davis. The project is a collaborative effort with researchers at the University of South Carolina and at the New York State Institute for Basic Research on Developmental Disabilities. The goals of this study are to learn... » FULL ARTICLE
Genetic disorders in children: An assessment of parental coping strategies and positive growth Following on from our earlier study of how parents disclose a diagnosis of fragile X syndrome to their children, we would like to further understand your experiences surrounding your child, including your emotional reaction and psychological well-being. In particular, we are interested in the support that you as a caregiver have available, and how this helped you to cope with the experience. This is a questionnaire that you can do online. You can do this study even if... » FULL ARTICLE